OVERVIEW

Management of HR+/HER2- Early Breast Cancer Knowledge Centre is organized by Springer Healthcare IME.

Description:
Worldwide, breast cancer is one of the most common malignancies, and is the leading cause of cancer-related deaths in women. The most prevalent subtype is HR+/HER2- disease, accounting for approximately 70% of all cases, with 90% of these patients diagnosed in the early stages when there is the potential for cure. Despite this, approximately 1 in 6 patients diagnosed with HR+ HER2- early breast cancer will experience disease recurrence within 5 years of treatment.

This risk of recurrence is individualized for each patient, and calculated based on factors including nodal involvement, tumor size, and tumor biology, with a variety of approved and emerging treatment options available dependent on these variables.

This expert-led program aims to improve the individualized management of HR+/HER2- early breast cancer through education on recurrence risk classification, current evidence-based guidelines, and new and emerging therapies.

There will also be guidance on integrating shared decision-making into your practice drawing on insights from a patient on how best to communicate.

Learning Objectives:
Following completion of this independent educational program, you will be able to:?
• Classify the risk of recurrence in patients with HR+/HER2- early breast cancer based on key prognostic variables
• Debate the appropriate treatment, both current and emerging, for HR+/HER2- early breast cancer based on recurrence risk
• Integrate tools and guidance on shared decision-making to ensure patient preference is a high priority when choosing the management strategy